The PACMAN AMI (Vascular Effects of Alirocumab in Acute MI-Patients) trial (ClinicalTrials.gov Identifier: NCT03067844) is examining the effects of PCSK9-inhibiting monoclonal antibody, alirocumab on coronary atherosclerosis in acute MI patients via NIRS, IVUS and OCT. This evidence concerns the gene PCSK9 and coronary atherosclerosis.